Cargando…

Immune checkpoint inhibitors as a real hope in advanced urothelial carcinoma

Metastatic urothelial cancer is an aggressive disease associated with a poor prognosis. In the first-line setting, platinum-based chemotherapy is the standard of care but resistance rapidly occurs. After failure of platinum-based therapy and in cisplatin-ineligible patients, therapeutic options are...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seront, Emmanuel, Catala, Gaëtan, Dermine, Alexandre, Lejeune, Sarah, Rysselinck, Stephane
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Science Ltd 2018
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6234462/ https://www.ncbi.nlm.nih.gov/pubmed/30457576 http://dx.doi.org/10.4155/fsoa-2018-0033

Ejemplares similares

The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma
por: Houssiau, Hélène, et al.
Publicado: (2022)

Improving the role of immune checkpoint inhibitors in the management of advanced urothelial carcinoma, where do we stand?
por: Houssiau, Hélène, et al.
Publicado: (2022)

Laparoscopic partial cystectomy for venous malformation of the bladder
por: Radermecker, Lea, et al.
Publicado: (2020)

Isolated peritoneal carcinomatosis in prostate cancer: from a successful hormonal management to a review of the literature
por: Delchambre, Emilie, et al.
Publicado: (2021)

Immune checkpoint inhibitors for urothelial carcinoma
por: Kim, Hyung Suk, et al.
Publicado: (2018)

Immune Checkpoint Inhibitors in the Management of Urothelial Carcinoma
por: Patel, Aakash, et al.
Publicado: (2021)

Biomarkers of the Response to Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Chen, Siteng, et al.
Publicado: (2020)

Effectiveness and safety of immune checkpoint inhibitor monotherapy in advanced upper tract urothelial carcinoma: A multicenter, retrospective, real‐world study
por: Su, Ruopeng, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitor therapy for advanced urothelial carcinoma in real-life clinical practice: results of a multicentric, retrospective study
por: Váradi, Melinda, et al.
Publicado: (2023)

Immune checkpoint inhibitors in osteosarcoma: A hopeful and challenging future
por: Zhang, Zeng, et al.
Publicado: (2022)

Adverse Effects and Toxicity of Immune Checkpoint Inhibitors For Patients With Urothelial Carcinoma
por: Wang, Di, et al.
Publicado: (2021)

Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma—A Review
por: Walia, Arman S., et al.
Publicado: (2021)

The impact of mutational clonality in predicting the response to immune checkpoint inhibitors in advanced urothelial cancer
por: Boll, Lilian Marie, et al.
Publicado: (2023)

New prognostic model in patients with advanced urothelial carcinoma treated with second-line immune checkpoint inhibitors
por: Bamias, Aristotelis, et al.
Publicado: (2023)

Disitamab vedotin in combination with immune checkpoint inhibitors for locally and locally advanced bladder urothelial carcinoma: a two-center’s real-world study
por: Wei, Yongbao, et al.
Publicado: (2023)

First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis
por: Lin, Chang-Ting, et al.
Publicado: (2022)

Trends in Checkpoint Inhibitor Therapy for Advanced Urothelial Cell Carcinoma at the End of Life: Insights from Real‐World Practice
por: Parikh, Ravi B., et al.
Publicado: (2019)

Predictive biomarkers for immune checkpoint inhibitor response in urothelial cancer
por: Parent, Pauline, et al.
Publicado: (2023)

Development of secondary urothelial carcinoma following complete response to immune checkpoint inhibitors
por: Lavoie, Jean-Michel, et al.
Publicado: (2021)

Prognostic and Predictive Factors in Advanced Urothelial Carcinoma Treated with Immune Checkpoint Inhibitors: A Review of the Current Evidence
por: Rebuzzi, Sara Elena, et al.
Publicado: (2021)

TERT promoter mutations and other prognostic factors in patients with advanced urothelial carcinoma treated with an immune checkpoint inhibitor
por: de Kouchkovsky, Ivan, et al.
Publicado: (2021)

Immunotherapy With Checkpoint Inhibitors in FGFR-Altered Urothelial Carcinoma
por: Benjamin, David J, et al.
Publicado: (2022)

Immune checkpoint inhibitors in urothelial cancer: recent updates and future outlook
por: Gopalakrishnan, Dharmesh, et al.
Publicado: (2018)

A Comprehensive Review of US FDA-Approved Immune Checkpoint Inhibitors in Urothelial Carcinoma
por: Hsu, Fu-Shun, et al.
Publicado: (2017)

Predicting immune checkpoint inhibitor response in urothelial carcinoma: another step in personalised medicine?
por: Niegisch, Günter
Publicado: (2019)

Metastatic Urothelial Carcinoma from Transplanted Kidney with Complete Response to an Immune Checkpoint Inhibitor
por: Chiang, Ryan S., et al.
Publicado: (2020)

Subsequent Systemic Therapy following Platinum and Immune Checkpoint Inhibitors in Metastatic Urothelial Carcinoma
por: Hong, Joohyun, et al.
Publicado: (2022)

Advances in Immune Checkpoint Inhibitors for Advanced Hepatocellular Carcinoma
por: Chen, Yue, et al.
Publicado: (2022)

Comprehensive immune profiling of patients with advanced urothelial or renal cell carcinoma receiving immune checkpoint blockade
por: Lavoie, Jean-Michel, et al.
Publicado: (2022)

Treatment options for advanced urothelial cancer after progression on chemotherapy and immune checkpoint inhibitors: a literature review
por: Koshkin, Vadim S., et al.
Publicado: (2021)

Advances in immune checkpoint inhibitors for hepatocellular carcinoma
por: Han, Ji Won, et al.
Publicado: (2021)

Efficacy of Immune Checkpoint Inhibitors in Upper Tract Urothelial Carcinomas: Current Knowledge and Future Directions
por: Thouvenin, Jonathan, et al.
Publicado: (2021)

Pseudoprogression and hyperprogression during immune checkpoint inhibitor therapy for urothelial and kidney cancer
por: Soria, Francesco, et al.
Publicado: (2018)

Machine Learning for Prediction of Survival Outcomes with Immune-Checkpoint Inhibitors in Urothelial Cancer
por: Abuhelwa, Ahmad Y., et al.
Publicado: (2021)

Immune Checkpoint Inhibitors in Urothelial Bladder Cancer: State of the Art and Future Perspectives
por: Roviello, Giandomenico, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer
por: Zhu, Alec, et al.
Publicado: (2023)

Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors
por: Nuzzo, Pier Vitale, et al.
Publicado: (2020)

Immune Checkpoint Targeted Therapy in Glioma: Status and Hopes
por: Qi, Yangzhi, et al.
Publicado: (2020)

Combination Biomarker of Immune Checkpoints Predict Prognosis of Urothelial Carcinoma
por: Tsai, Chung-Ying, et al.
Publicado: (2021)

Safety and Efficacy of Immune Checkpoint Inhibitors for Patients With Metastatic Urothelial Carcinoma and End-Stage Renal Disease: Experiences From Real-World Practice
por: Kuo, Ming-Chun, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_3neo8nmqpgfh3clliatbt0k87n